- Published on
Emergency and Acute Medicine: Von Willebrand Disease
Von Willebrand Disease is the most common inherited bleeding disorder and results from either a deficiency or dysfunction of von Willebrand factor, a key protein involved in hemostasis. vWF plays two major roles: it mediates platelet adhesion to the vascular endothelium and serves as a carrier protein for Factor VIII. The disease affects approximately 1–2% of the general population and is usually inherited, though acquired forms can occur.
There are three major types of vWD. Type 1, the most common (about 70%), is a quantitative deficiency of vWF and is typically inherited in an autosomal dominant pattern, with symptoms ranging from mild to moderate bleeding. Type 2 involves qualitative defects in vWF function and includes several subtypes (2A, 2B, 2M, 2N), with type 2N characterized by reduced binding to factor VIII, leading to more significant coagulopathy. Type 3 is rare, inherited in an autosomal recessive pattern, and represents a severe deficiency or absence of vWF, resulting in serious bleeding manifestations. In addition to genetic causes, acquired vWD may occur due to conditions such as malignancies, autoimmune diseases, hypothyroidism, or certain medications.
Clinical presentation varies widely depending on the type and severity of the disorder. Many patients with type 1 or mild type 2 disease may be asymptomatic, while those with more severe forms present with mucocutaneous bleeding, including easy bruising, recurrent epistaxis, gum bleeding, and menorrhagia. Gastrointestinal bleeding, prolonged bleeding after procedures, and postoperative hemorrhage may also occur. In more severe cases, such as type 3 disease, patients may develop deep tissue bleeding and hemarthroses, resembling hemophilia. A detailed history often reveals a family history of bleeding and recurrent minor bleeding episodes, especially in pediatric and adolescent populations.
Physical examination is often normal, although findings may include ecchymoses, hematomas, or joint swelling in more severe cases. Special considerations include pregnancy, during which vWF levels may increase temporarily, often leading to fewer bleeding complications; however, levels drop postpartum, increasing the risk of delayed bleeding. In children, clinicians must always consider nonaccidental trauma when unexplained bruising or bleeding is present.
Diagnosis relies on laboratory evaluation. Platelet counts and morphology are typically normal, and prothrombin time (PT) is usually normal. Partial thromboplastin time (PTT) may be mildly prolonged due to reduced factor VIII levels. Specific tests include measurement of vWF antigen and activity, particularly the ristocetin cofactor assay, which evaluates vWF function through platelet agglutination. Bleeding time may be prolonged in more severe types but is less commonly used כיום due to poor reproducibility.
Management focuses on controlling bleeding and correcting the underlying defect. Initial stabilization includes standard resuscitation measures with fluids and blood products as needed, along with direct pressure to bleeding sites. The cornerstone of therapy for mild to moderate disease is Desmopressin, which promotes the release of endogenous vWF and increases factor VIII levels. It is administered at 0.3 μg/kg IV or subcutaneously (maximum 20 μg), or 300 μg intranasally (150 μg if <50 kg), with peak effect occurring within 30–60 minutes and lasting 6–8 hours. It is most effective in type 1 disease, variably effective in type 2, and not useful in type 3.
For severe bleeding or type 3 disease, vWF replacement therapy is required, typically using Humate-P at doses of 20–40 units/kg IV. Antifibrinolytic agents such as Tranexamic acid (20–25 mg/kg PO or IV every 8 hours) and Aminocaproic acid (50–60 mg/kg PO or IV every 4–6 hours) are useful adjuncts, particularly for mucosal bleeding. Although Cryoprecipitate and Fresh frozen plasma may contain vWF, they are generally reserved for life-threatening situations when safer products are unavailable due to infection risk. Patients should avoid antiplatelet medications such as NSAIDs, which can worsen bleeding.
Disposition depends on severity. Patients with significant or ongoing bleeding, especially those requiring IV therapy, should be admitted and managed in consultation with hematology. Those with controlled bleeding and reliable follow-up may be discharged with clear instructions. Long-term management includes hematology referral for definitive diagnosis, planning before surgical procedures, and education regarding bleeding risk.
A key clinical pearl is that patients may not know their specific subtype of bleeding disorder, and in emergency situations with significant bleeding, empiric treatment (e.g., FFP or vWF-containing products) may be necessary while awaiting definitive diagnosis.
Von Willebrand Disease is the most common inherited bleeding disorder and results from either a deficiency or dysfunction of von Willebrand factor, a key protein involved in hemostasis. vWF plays two major roles: it mediates platelet adhesion to the vascular endothelium and serves as a carrier protein for Factor VIII. The disease affects approximately 1–2% of the general population and is usually inherited, though acquired forms can occur.
There are three major types of vWD. Type 1, the most common (about 70%), is a quantitative deficiency of vWF and is typically inherited in an autosomal dominant pattern, with symptoms ranging from mild to moderate bleeding. Type 2 involves qualitative defects in vWF function and includes several subtypes (2A, 2B, 2M, 2N), with type 2N characterized by reduced binding to factor VIII, leading to more significant coagulopathy. Type 3 is rare, inherited in an autosomal recessive pattern, and represents a severe deficiency or absence of vWF, resulting in serious bleeding manifestations. In addition to genetic causes, acquired vWD may occur due to conditions such as malignancies, autoimmune diseases, hypothyroidism, or certain medications.
Clinical presentation varies widely depending on the type and severity of the disorder. Many patients with type 1 or mild type 2 disease may be asymptomatic, while those with more severe forms present with mucocutaneous bleeding, including easy bruising, recurrent epistaxis, gum bleeding, and menorrhagia. Gastrointestinal bleeding, prolonged bleeding after procedures, and postoperative hemorrhage may also occur. In more severe cases, such as type 3 disease, patients may develop deep tissue bleeding and hemarthroses, resembling hemophilia. A detailed history often reveals a family history of bleeding and recurrent minor bleeding episodes, especially in pediatric and adolescent populations.
Physical examination is often normal, although findings may include ecchymoses, hematomas, or joint swelling in more severe cases. Special considerations include pregnancy, during which vWF levels may increase temporarily, often leading to fewer bleeding complications; however, levels drop postpartum, increasing the risk of delayed bleeding. In children, clinicians must always consider nonaccidental trauma when unexplained bruising or bleeding is present.
Diagnosis relies on laboratory evaluation. Platelet counts and morphology are typically normal, and prothrombin time (PT) is usually normal. Partial thromboplastin time (PTT) may be mildly prolonged due to reduced factor VIII levels. Specific tests include measurement of vWF antigen and activity, particularly the ristocetin cofactor assay, which evaluates vWF function through platelet agglutination. Bleeding time may be prolonged in more severe types but is less commonly used כיום due to poor reproducibility.
Management focuses on controlling bleeding and correcting the underlying defect. Initial stabilization includes standard resuscitation measures with fluids and blood products as needed, along with direct pressure to bleeding sites. The cornerstone of therapy for mild to moderate disease is Desmopressin, which promotes the release of endogenous vWF and increases factor VIII levels. It is administered at 0.3 μg/kg IV or subcutaneously (maximum 20 μg), or 300 μg intranasally (150 μg if <50 kg), with peak effect occurring within 30–60 minutes and lasting 6–8 hours. It is most effective in type 1 disease, variably effective in type 2, and not useful in type 3.
For severe bleeding or type 3 disease, vWF replacement therapy is required, typically using Humate-P at doses of 20–40 units/kg IV. Antifibrinolytic agents such as Tranexamic acid (20–25 mg/kg PO or IV every 8 hours) and Aminocaproic acid (50–60 mg/kg PO or IV every 4–6 hours) are useful adjuncts, particularly for mucosal bleeding. Although Cryoprecipitate and Fresh frozen plasma may contain vWF, they are generally reserved for life-threatening situations when safer products are unavailable due to infection risk. Patients should avoid antiplatelet medications such as NSAIDs, which can worsen bleeding.
Disposition depends on severity. Patients with significant or ongoing bleeding, especially those requiring IV therapy, should be admitted and managed in consultation with hematology. Those with controlled bleeding and reliable follow-up may be discharged with clear instructions. Long-term management includes hematology referral for definitive diagnosis, planning before surgical procedures, and education regarding bleeding risk.
A key clinical pearl is that patients may not know their specific subtype of bleeding disorder, and in emergency situations with significant bleeding, empiric treatment (e.g., FFP or vWF-containing products) may be necessary while awaiting definitive diagnosis.
0 Comments
